5-Hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depressions. A double-blind controlled study.
Through a controlled double-blind study in 30 hospitalized patients affected with endogenous depression, the antidepressant action of the combination of nialamide+l-5-HTP has been evaluated and compared with a control group which only received nialamide (+ placebo). The patients treated with nialamide + l-5-HTP achieved a fuller recovery than those who were treated with nialamide alone. The treatment with nialamide + l-5-HTP proved to have a shorter delay of onset. Side effects showed no marked differences except for the orthostatic hypotension which was less apparent in those patients treated with nialamide + l-5-HTP.
D006916:5-Hydroxytryptophan / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009526:Nialamide / Q000009:adverse effects / Q000627:therapeutic use*; D009567:Nitrazepam / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D013997:Time Factors
D009567:Nitrazepam; D006916:5-Hydroxytryptophan; D009526:Nialamide